SparingVision Eyes The Clinic With Two Assets After €75m Series B Raise
Funded Until Second Half Of 2025
Executive Summary
The French firm will use the funds to establish proof-of-concept for two gene therapy programs in a rare eye condition as it strives to become a world leader in ophthalmic genomic medicine, its CEO tells Scrip.
You may also be interested in...
Certa Plans Pivotal Scleroderma Trial As GPCR Antagonist Hits Phase II Bullseye
Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.
Idorsia’s Clazosentan Fails Yet Another Pivotal Brain Injury Trial As Cash Runway Dwindles
Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.
Sanofi Reports Uninspiring Q4 Sales Amid Skepticism On Dupixent’s COPD Potential
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.